Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Sep 26, 2026
Exxon Mobil (XOM) +40% YTD: Can the Stock Reach $200?

Exxon Mobil (XOM) +40% YTD: Can the Stock Reach $200?

Key Takeaways

  • The selected stock price target is $200, roughly 20% above recent trading levels and matching the top of the analyst target range.
  • Rising crude prices and strong second-quarter earnings are the primary bullish forces behind the stock's 40% year-to-date advance.
  • The biggest risk is a pullback in oil prices, with the U.S. Energy Information Administration projecting Brent crude to fall toward $79 by 2027.
  • Key support levels sit near the 50-day moving average around $155 and the 200-day moving average near $152; the 52-week high near $176 is the immediate resistance level to clear.
  • Reaching $200 is plausible but depends far more on the trajectory of crude prices than on the company's own execution.

Why the $200 Level Matters to Investors

The $200 mark has become a focal point of market discussion because it coincides with the most bullish published analyst price forecasts. Research firm Jefferies recently lifted its analyst price target on XOM to $200 from $184, while S&P Global data shows the broader consensus average sits near $171, with a low estimate of $142 and a high of $200. As a round number with roughly 20% upside from current levels, $200 also carries psychological significance for investors tracking the energy rally.

Drivers Behind the Recent Rally

XOM's advance has been powered by a sharp rise in oil prices. Brent crude climbed from the low $60s to near $96 per barrel, reflecting Middle East supply disruptions and tight product markets. That backdrop helped Exxon Mobil report $14.5 billion in second-quarter earnings, more than $17 billion in free cash flow, and a reduction in net debt of more than $7 billion. Production growth has reinforced the story. Guyana output ran at roughly 900,000 barrels per day, while Permian Basin production hit a record 1.8 million oil-equivalent barrels per day. The company has also accumulated about $16.3 billion in structural cost savings since 2019, working toward a $20 billion target by 2030, and is executing a $20 billion share buyback program for 2026. I also checked this using Tickeron’s AI Trend Prediction Engine to see how the macro backdrop aligns with historical patterns.

Risks That Could Halt Further Gains

The path to $200 is heavily tied to commodity prices rather than factors Exxon Mobil directly controls. If crude oil fades from the mid-$90s, the earnings momentum supporting the stock could stall. The EIA's projection of Brent falling toward $79 by 2027 illustrates how quickly the macro tailwind could reverse. Demand signals also present a challenge: Chinese oil consumption is expected to decline in 2026 for a third consecutive year, which could cap further price gains. Even within the sector, XOM has lagged peers during the rally. CVX rose about 44% year to date, and the Energy Select Sector SPDR ETF (XLE) advanced roughly 48%, meaning the market has favored other energy names during this cycle.

Wall Street Price Targets and Views

Wall Street's price target range reflects genuine disagreement. Bullish calls include Jefferies at $200, Piper Sandler at $185, and Wells Fargo near $182, while Morgan Stanley and Barclays each sit near $177. On the more cautious side, HSBC carries a $158 target and TD Cowen a $168 target. The average target of roughly $171 implies only single-digit upside from current levels, underscoring that the $200 objective is an outlier that would require sustained oil strength rather than baseline assumptions.

Important Technical Levels to Watch

From a technical analysis perspective, XOM is trading above its 50-day moving average near $155 and its 200-day moving average near $152, confirming a healthy long-term uptrend. The 52-week high of $176.41 is the immediate hurdle, while $200 stands as the next major psychological ceiling. A decisive break above the $176 area would clear the path toward higher levels, while a loss of the $152-to-$155 zone would weaken the bullish structure. From what I see, holding these moving averages remains key to sustaining momentum.

Incorporating AI Signals in My Analysis

I frequently use AI Daily Buy/Sell Signals from Tickeron as part of my routine when evaluating energy names like XOM. The tool applies artificial intelligence to scan thousands of stocks and ETFs, delivering Buy, Sell, or Hold signals based on technical behavior and shifting market conditions. It helps me spot potential trend changes more efficiently without replacing my own fundamental review, and I find it especially useful for monitoring how commodity-driven moves play out in real time.

My Take on the Path to $200

A move to $200 for XOM appears achievable but far from guaranteed. The strongest supporting factors are elevated crude prices, record Permian output, growing Guyana free cash flow, and a sizable buyback program that lifts per-share value. The primary risks are a retreat in oil prices, softening global demand, and the reality that the stock has already logged a substantial gain. Investors should monitor crude price stability, refining margins, Middle East supply conditions, and whether the stock can hold above its key moving averages. Reaching $200 likely requires oil to remain near current levels into the fourth quarter — a scenario that is possible, but not one any investor should treat as a certainty.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: XOM

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Aroon Indicator for XOM shows an upward move is likely

XOM's Aroon Indicator triggered a bullish signal on August 25, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 302 similar instances where the Aroon Indicator showed a similar pattern. In 199 of the 302 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 66%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 35 of 59 cases where XOM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 59%.

Following a +2.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where XOM advanced for three days, in 232 of 373 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.

Bearish Trend Analysis

The 10-day RSI Indicator for XOM moved out of overbought territory on August 24, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In 26 of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at 63%.

The Momentum Indicator moved below the 0 level on September 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XOM as a result. In 50 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 55%.

The Moving Average Convergence Divergence Histogram (MACD) for XOM turned negative on September 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 31 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 62%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XOM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 6 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 27, placing this stock better than average.

The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. XOM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 62 (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: XOM's P/B Ratio (2.546) is slightly higher than the industry average of (1.912). P/E Ratio (20.668) is within average values for comparable stocks, (16.706). Projected Growth (PEG Ratio) (1.376) is also within normal values, averaging (1.091). Dividend Yield (0.026) settles around the average of (0.034) among similar stocks. P/S Ratio (1.911) is also within normal values, averaging (3.764).

Notable companies

The most notable companies in this group are ExxonMobil Holdings Corporation (NYSE:XOM), Chevron Corp (NYSE:CVX), Petroleo Brasileiro Sa-Petrobras ADS (REP 1 Common Share) (NYSE:PBR), BP plc (NYSE:BP), Suncor Energy (NYSE:SU), YPF Sociedad Anonima (NYSE:YPF).

Industry description

Integrated oil companies are involved across nearly the entire oil value chain – from upstream operations like exploration and production, to downstream functions of refining and marketing. Exxon Mobil Corporation, Chevron Corporation and BP are major integrated oil companies. Their bottom lines’ response to crude oil prices could depend on the proportion of upstream vs. downstream businesses; for example, if a company has substantial downstream business, the adverse impact on their upstream business due to falling crude prices could be mitigated by benefits to its downstream business.

Market Cap

The average market capitalization across the Integrated Oil Industry is 124.76B. The market cap for tickers in the group ranges from 63.2K to 660.33B. XOM holds the highest valuation in this group at 660.33B. The lowest valued company is CRRDF at 63.2K.

High and low price notable news

The average weekly price growth across all stocks in the Integrated Oil Industry was -3%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 1%. SHEL experienced the highest price growth at 1%, while SLNG experienced the biggest fall at -6%.

Volume

The average weekly volume growth across all stocks in the Integrated Oil Industry was -52%. For the same stocks of the Industry, the average monthly volume growth was -24% and the average quarterly volume growth was -52%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 40
P/E Growth Rating: 52
Price Growth Rating: 43
SMR Rating: 55
Profit Risk Rating: 27
Seasonality Score: 28 (-100 ... +100)
View a ticker or compare two or three
XOM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a distributer of crude oil, natural gas and petroleum products

Industry IntegratedOil

Industry
Integrated Oil
Address
22777 Springwoods Village Parkway
Phone
+1 972 940-6000
Employees
57900
Web
https://www.corporate.exxonmobil.com
Interact to see
Advertisement
INSM shares are surging approximately +10% in premarket trading on Monday, March 23, 2026, from a prior close of $136.00, placing the premarket price near $149.60. The primary catalyst is the release of positive topline results from the Phase 3 ENCORE trial of ARIKAYCE® in patients with newly diagnosed or recurrent MAC (Mycobacterium avium complex) lung disease — a readout Insmed had flagged as expected in "March or April 2026".
CF shares are trading approximately -6% lower in Monday's premarket session, dropping from a Friday close of $124.90 to approximately $117.41. Primary catalyst: President Trump announced a five-day pause on strikes against Iranian energy infrastructure following "very good" diplomatic signals, triggering a sharp unwind of the geopolitical risk premium embedded in fertilizer stocks.
APGE shares surged approximately 16% in premarket trading on March 23, 2026, after the company announced positive 52-week data from Part A of its Phase 2 APEX clinical trial. The primary catalyst is a highly anticipated clinical readout showing that zumilokibart (APG777) delivered durable and deepening responses in patients with moderate-to-severe atopic dermatitis at both every 3-month and 6-month dosing intervals.
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.
SEDG is indicated down roughly 9% in premarket trading, following a strong advance in the prior regular session. The pullback comes after shares rallied on optimism around new product launches and an analyst upgrade, leaving the stock vulnerable to profit-taking and volatility.
NTGR shares surged approximately 11% in premarket trading on March 24, 2026, building on a roughly 20% overnight jump in the prior session. The primary catalyst is a landmark Federal Communications Commission (FCC) ruling that prohibits all imports of consumer routers manufactured overseas, citing national security concerns.
ANNA is surging approximately +20.00% in Tuesday's premarket session, rebounding sharply from Monday's -22.84% decline. The primary catalyst remains the ongoing U.S.-Iran military conflict, which disrupted Qatari LNG exports and drove European benchmark natural gas prices to multi-year highs.
Concentrix Corporation (CNXC) shares are falling approximately 11% in Tuesday's premarket session after the company released its fiscal Q1 2026 earnings report before market open. Adjusted diluted EPS came in at $2.61, missing the Wall Street consensus estimate of approximately $2.64.
Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63. The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints.
IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23. The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.
Shares of Circle Internet Group (CRCL) are down approximately 9% in Tuesday morning trading, extending a pullback from recent multi-month highs above $126. The primary catalyst appears to be a broad crypto-sector risk-off wave, with Bitcoin sliding below $69,000 and the Fear & Greed Index dropping to extreme fear territory.
ALM shares are indicated down about 11% in early Tuesday trading after closing the prior session at $16.93. The move comes after a powerful multi‑month rally that took the stock from below $3 to an intraday high of $22.55 earlier in March, leaving it vulnerable to profit-taking and volatility.​
LUNR shares are indicated down about 7% in Tuesday premarket trading after closing the last regular session at $20.31. The pullback follows a powerful rally driven by strong 2026 revenue guidance of $900 million–$1 billion and upbeat analyst commentary, including price target hikes and buy ratings.
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.
Shares of Enliven Therapeutics (ELVN) are surging approximately +15% in premarket trading on March 25, 2026, driven by renewed investor enthusiasm around the company's advancing clinical program for ELVN-001 in chronic myeloid leukemia (CML). The stock's prior closing price on March 24, 2026 was $31.15, placing the premarket indicated price near $35.82.
AVXL shares are down approximately 29% in premarket trading on Wednesday, March 25, 2026, falling to roughly $2.97 from the prior close of $4.19. The primary catalyst is Anavex's formal withdrawal of its marketing authorization application (MAA) for blarcamesine from the European Union, announced in the early hours of March 25, 2026.